Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
Caplin Point Laboratories is currently trading at Rs. 1011.00, up by 25.75 points or 2.61% from its previous closing of Rs. 985.25 on the BSE.
The scrip opened at Rs. 999.00 and has touched a high and low of Rs. 1033.00 and Rs. 989.75 respectively. So far 10247 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1361.50 on 09-Apr-2015 and a 52 week low of Rs. 246.00 on 10-Jul-2014.
Last one week high and low of the scrip stood at Rs. 1033.50 and Rs. 946.00 respectively. The current market cap of the company is Rs. 1495.89 crore.
The promoters holding in the company stood at 67.81% while Institutions and Non-Institutions held 1.60% and 30.59% respectively.
Caplin Point Laboratories has received EU GMP approval for its small volume sterile injectable liquids facility at Chennai. The site was inspected by the EU authorities in March 2015 and has been certified as compliant with the guidelines. The facility is capable of manufacturing Liquid Injectables in Vials, Ampoules, Lyophilized Vials and Opthalmic dosages.
EU approval grants access not only to the European Union, but also several other countries in the Regulated domain through mutual recognition process.
Caplin Point Laboratories is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1687.55 |
Dr. Reddys Lab | 1109.15 |
Cipla | 1463.15 |
Lupin | 1969.05 |
Zydus Lifesciences | 868.25 |
View more.. |